A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
about
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDSA combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSPrediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoRole of Marine Natural Products in the Genesis of Antiviral AgentsFactors in AIDS dementia complex trial design: results and lessons from the abacavir trialAbacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.Management protocol for abacavir-related hypersensitivity reaction.Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infectionPharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adultsPopulation pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.Trizivir.Initial antiretroviral therapy in chronically-infected HIV-positive adults.Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients.Abacavir hypersensitivity reaction.Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.
P2860
Q24200188-D9D96CF3-5268-4199-8076-57BB71C18CCBQ24239831-891FBF58-8315-47CA-B091-B0D93E98E863Q24535740-3C2B62DC-C347-4275-8641-E0DF867DC6EDQ26796360-47C4BD07-86D9-4A91-BE1A-58F80FAF33FFQ28469174-4C5E8CB3-AC6F-4C1A-9407-3EEF1F6C4236Q33720839-ADDC5662-4FE9-4652-908E-3A8D66CB4933Q33838939-74B9E3BB-B7CD-46BB-967A-E7EDE94CD5ACQ33977187-59BAFC55-8CAA-4E6F-AC8E-3590BFED04DEQ33979817-D10B4EE0-FA58-4A8F-BFF5-12799E249E18Q33980164-6F29E5FD-B78C-4CC6-B5EA-EDE91BD9E410Q33980172-A7851E3A-8430-4EB0-A0B4-EF6DF8B0BFB3Q34628638-20742B78-DF54-4670-AE82-817F36CD1A25Q35688173-9B595C39-AFC3-428C-84E3-360A9647E0C7Q35826691-F3117214-B873-49AD-9A39-CD65B235F3E2Q36322100-7FBE5AE4-6CCA-4CD7-B3A4-68EA74CE076FQ36739802-D402BD33-782F-4912-9045-4607EAC3E896Q37399199-C5A3B69B-FB6B-4352-8BEC-C36D1FE44E9BQ41269351-19860007-8ED5-4A1C-A413-73478925D693Q42259925-C0944D74-A341-4E01-9B1D-E1C8060D78AEQ43933908-26DAA205-F73F-440A-971A-53E2DFEB444FQ46789879-4429D00E-36D0-43F6-9CC4-093C942170C1Q49037532-F8AE70A5-6DA5-4E8B-BDE8-7AC72CC9A1E3
P2860
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@en
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@nl
type
label
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@en
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@nl
prefLabel
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@en
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@nl
P2093
P1433
P1476
A dose-ranging study to evalua ...... iral treatment-naive subjects.
@en
P2093
R E Lanier
R P Harrigan
S M Tortell
S Staszewski
P304
P356
10.1097/00002030-199816000-00001
P407
P577
1998-11-01T00:00:00Z